TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06192303

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoalveolar lavage and pathogen metagenomic sequencing
Description: After the patient is enrolled, traditional pathogen testing will be improved, and the clinical physician will make a preliminary diagnosis based on routine pathogen testing, clinical manifestations, infection indicators, and imaging. Within 24 hours of initial diagnosis, bronchoalveolar lavage and pathogen metagenomic sequencing were performed, and BALF mNGS results were fed back to clinical physicians (without interfering with clinical decision-making). Clinical treatment data of patients were collected at 72 hours, 7 days, 14 days, and 28 days after the start of treatment, and follow-up and efficacy evaluation were conducted. Finally, a review committee consisting of two senior respiratory physicians and one imaging physician conducted a systematic review of cases to make the final diagnosis of enrolled patients (as the gold standard), analyzing the accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of BALF mNGS in diagnosing CIP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoalveolar lavage and pathogen metagenomic sequencing
Description: After the patient is enrolled, traditional pathogen testing will be improved, and the clinical physician will make a preliminary diagnosis based on routine pathogen testing, clinical manifestations, infection indicators, and imaging. Within 24 hours of initial diagnosis, bronchoalveolar lavage and pathogen metagenomic sequencing were performed, and BALF mNGS results were fed back to clinical physicians (without interfering with clinical decision-making). Clinical treatment data of patients were collected at 72 hours, 7 days, 14 days, and 28 days after the start of treatment, and follow-up and efficacy evaluation were conducted. Finally, a review committee consisting of two senior respiratory physicians and one imaging physician conducted a systematic review of cases to make the final diagnosis of enrolled patients (as the gold standard), analyzing the accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of BALF mNGS in diagnosing CIP.
Study: NCT06326944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound- guided Fascia Transversalis plane block
Description: Ultrasound probe will be placed in a transverse orientation above the iliac crest; and the external oblique, internal oblique (IO), and transversus abdominis TA muscles will be identified and traced posteriorly until first the TA muscle and then the IO muscle tapered into their common aponeurosis, adjacent to the quadratus lumborum muscle. The tip of a 22-gauge 80-mm block needle will be positioned just deep to the TA muscle and its aponeurosis at the point where the TA is tapered off. 0.4 ml/kg bupivacaine 0.25% will be injected into the plane between the TA and underlying transversalis fascia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Transversus abdominus plane block
Description: the probe will be placed transversely in the mid-axillary line between the iliac crest and the costal margin at the level of the umbilicus. The external oblique, internal oblique and transversus abdominis muscles and their fascias will be visualized. A 22 gauge, 80 mm needle will be introduced anteriorly and in the plane of the ultrasound probe, and on entering the plane between IO and TA, 2 ml of 0.9% saline will be injected to verify the correct position of the needle. Following negative aspiration, 0.4 ml/kg of bupivacaine 0.25% will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: Pethidine IV will be given as rescue analgesia (0.5 mg/kg) if the FLACC pain score was more than 4 , the maximum allowed dose is 1mg/kg every 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: Pethidine IV will be given as rescue analgesia (0.5 mg/kg) if the FLACC pain score was more than 4 , the maximum allowed dose is 1mg/kg every 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: patients will be given paracetamol (15 mg /kg/8 hrs ).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: patients will be given paracetamol (15 mg /kg/8 hrs ).
Study: NCT04469569

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HPV-PROTECT
Description: HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HPV-PROTECT
Description: HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
Study: NCT06471985

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Music and pain
Description: In both arms of the study the participant will take the same pain test. They will either listen to Enya or slayer, depending on the arm

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Music and pain
Description: In both arms of the study the participant will take the same pain test. They will either listen to Enya or slayer, depending on the arm
Study: NCT05525468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-180935
Description: TDM-180935 topical ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-180935
Description: TDM-180935 topical ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for TDM-180935 topical ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for TDM-180935 topical ointment
Study: NCT06282055

Intervention type: OTHER
Intervention: No intervention
Description: Observational prospective longitudinal data collection
Study: NCT06003062

Intervention type: DRUG
Intervention: Narcissus Tazetta Bulb Extract and Novel Hemp Extract
Description: Topical nightly application of phytonutraceutical
Study: NCT05144425

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with and without using pneumatic tourniquet
Description: The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of\<8 g/dL or patient with symptomatic anemia.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: total knee arthroplasty with and without using pneumatic tourniquet
Description: The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of\<8 g/dL or patient with symptomatic anemia.
Study: NCT05213871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization
Description: For IASTM, the subject will be seated in a comfortable position. The subject's forehead will be rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2T blade will be cleaned with an alcohol pad. The M2T blade will be used, at an angle of 45 without causing discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. Subjects will be instructed to put an ice pack on the area if they feel any burning sensations after the session. This procedure will be repeated twice a week for four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release therapy
Description: Firstly, the subject will lay supine with no pillow under his/ her head then the subject will rotate his/her head and neck away from the side which will be treated. Therapist will sit or stand at the corner, edge or top of the treatment table and therapist will place one hand proximal to the shoulder with skin on skin and therapist's fingers pointing towards the subject's elbow on the same side. Other hand of the therapist will be placed inferior to the subject's jaw (body of the mandible), using it as a handle, with fingers pointing towards the top of the subject's head. Then therapist will lean into the subject to the tissue depth barrier, wait and follow each subtle release three-dimensionally. Therapist should avoid forcing the tissue or slipping or gliding over the skin. The technique should be applied for at least five minutes for optimal results. This procedure will be repeated twice a week for four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises (PCE)
Description: Postural correction exercises will be applied for patients in groups A and B. This program will be conducted according to the protocols of exercise will be performed as 3 sets of 10 repetitions each for 2 times/ week for 4 weeks. The patients will be instructed to continue the exercises as a daily home program to influence the self-correction kinesthetic awareness. Exercises will be performed while the patients in a neutral sitting posture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises (PCE)
Description: Postural correction exercises will be applied for patients in groups A and B. This program will be conducted according to the protocols of exercise will be performed as 3 sets of 10 repetitions each for 2 times/ week for 4 weeks. The patients will be instructed to continue the exercises as a daily home program to influence the self-correction kinesthetic awareness. Exercises will be performed while the patients in a neutral sitting posture
Study: NCT04256408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic transparenchymal interlobar fissure closure using Aeriseal
Description: Transbronchial or transparenchymal injection of AeriSeal into the interlobar collateral ventilation channels region to convert CV-positive lobes into CV-negative lobes.
Study: NCT05413642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recommended treatment schedule
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Treatment regimens different from the recommended one according to family physician personal practice
Study: NCT06535568

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated balloon
Description: Essential pro (iVascular, Barceona, Spain) paclitaxel eluting coronary balloon dilatation catheter is a rapid exchange catheter, also known as RX because it has a proximal simple lumen configuration and a distal coaxial dual lumen, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this Arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Essential pro (iVascular, Barceona, Spain) paclitaxel eluting coronary balloon dilatation catheter is a rapid exchange catheter, also known as RX because it has a proximal simple lumen configuration and a distal coaxial dual lumen, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this Arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (SAPT)
Description: The antithrombotic regimen is single antiplatelet therapy (SAPT). The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has been shown by these drugs in head-to-head trials versus clopidogrel in elderly PCI populations. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT)
Description: The antithrombotic regimen will follow the standard of care with a dual antiplatelet regimen (DAPT) per local preferences and international guidelines/ARC consensus paper. The type of agent and treatment duration will be selected according to the patient's clinical characteristics.
Study: NCT05201001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
Study: NCT05593991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated heels
Description: Each subject will undergo the following evaluations:~1. neutral barefoot position;~2. neutral barefoot position (re-test);~3. 3 cm rise of both heels, made with plastic spacer;~4. 7 cm rise of both heels, made with plastic spacer.
Study: NCT00889096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
Study: NCT05238584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial omentectomy
Description: Partial omentectomy: with preservation of the greater omentum at \>2 cm from the gastroepiploic arcade.
Study: NCT05426356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Intervention
Description: Surgical sacral fracture fixation and SI joint fusion using iFuse-TORQ

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Management
Description: Non-surgical management (NSM) is any treatment deemed appropriate for the subject that does not involve surgery.
Study: NCT05970653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
Study: NCT05201001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APX005M
Description: adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
Study: NCT06380023

Intervention type: DEVICE
Intervention: Enclosure barrier
Description: Surgical mask \& Enclosure tent compared with open suction

Intervention type: DEVICE
Intervention: Enclosure barrier
Description: Surgical mask \& Enclosure tent compared with open suction
Study: NCT06561737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: For the students in the experimental group, the application was first demonstrated on a model by the course instructor, after which each student was required to perform the application individually. While the students were performing the application, someone not part of the research team recorded them on their phones. During the application, two researchers independently assessed the student's skills using the application checklist. Afterward, the students were asked to watch their videos and evaluate themselves over a 15-day period. After 15 days, the students were called back and asked to perform the same application again. At this stage, the researchers once again evaluated the students independently.
Study: NCT05330949

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence Tomography Angiography, Uterine artry doppler
Description: vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence Tomography Angiography, Uterine artry doppler
Description: vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters
Study: NCT05504772

Intervention type: GENETIC
Intervention: Whole Genome Sequencing
Description: Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.

Intervention type: GENETIC
Intervention: Whole Genome Sequencing
Description: Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.
Study: NCT05781802

Intervention type: OTHER
Intervention: Level of pressure support
Description: Patients will be evaluated in two different conditions sequentially. The first condition will be at a clinically selected level of pressure support under stable clinical conditions.~This condition will be labeled according to P0.1:~* In case of P0.1\<2, the clinically selected level of pressure support will be considered High Pressure support.~* In case of P0.1\>2, the clinically selected level of pressure support will be considered Low Pressure support.~After data collection at clinically selected level of pressure support, pressure support level will be transiently increased or decreased (i.e. from high to low/ from low to high) to the lowest/highest clinically tolerated level, aiming at the predefined P01 thresholds, and then kept for 20 minutes under stable clinical conditions. Data collection will be repeated and then the clinically selected level of pressure support restored.
Study: NCT05040659

Intervention type: DEVICE
Intervention: AROMHA Longitudinal Smell Test
Description: The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.

Intervention type: DEVICE
Intervention: AROMHA Longitudinal Smell Test
Description: The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.

Intervention type: DEVICE
Intervention: AROMHA Longitudinal Smell Test
Description: The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.
Study: NCT05124626

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIRPE with two bars
Description: Minimally invasive repair of pectus excavatum utilizing two metallic bars
Study: NCT06554236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy and sensory training
Description: Physical therapy standard of care and 5 minutes of sensory training.